Cost Comparison of Linezolid Versus Vancomycin for Treatment of Complicated Skin and Skin-Structure Infection Caused by Methicillin-ResistantStaphylococcus aureusin Quebec | Zendy

M. Pettigrew | Zendy; Daniel J. G. Thirion | Zendy; Michael Libman | Zendy; Giovanni Zanotti | Zendy

Open Access

Cost Comparison of Linezolid Versus Vancomycin for Treatment of Complicated Skin and Skin-Structure Infection Caused by Methicillin-ResistantStaphylococcus aureusin Quebec

Author(s) -

M. Pettigrew,

Daniel J. G. Thirion,

Michael Libman,

Giovanni Zanotti

Publication year - 2012

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 38

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2012/585603

Subject(s) - linezolid , staphylococcus aureus , vancomycin , medicine , methicillin resistant staphylococcus aureus , staphylococcal skin infections , skin infection , microbiology and biotechnology , staphylococcal infections , antibiotics , intensive care medicine , dermatology , biology , bacteria , genetics

In Canada, complicated skin and skin-structure infection (cSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA) is usually treated with antibiotics in hospital, with a follow-up course at home for stable patients. The cost implications of using intravenous and oral linezolid instead of intravenous vancomycin in Canadian clinical practice have not been examined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research